52 related articles for article (PubMed ID: 7544649)
1. Antibodies to CD40 prevent Epstein-Barr virus-mediated human B-cell lymphomagenesis in severe combined immune deficient mice given human peripheral blood lymphocytes.
Murphy WJ; Funakoshi S; Beckwith M; Rushing SE; Conley DK; Armitage RJ; Fanslow WC; Rager HC; Taub DD; Ruscetti FW
Blood; 1995 Sep; 86(5):1946-53. PubMed ID: 7544649
[TBL] [Abstract][Full Text] [Related]
2. Targeting TfR1 with the ch128.1/IgG1 Antibody Inhibits EBV-driven Lymphomagenesis in Immunosuppressed Mice Bearing EBV
Martínez LE; Daniels-Wells TR; Guo Y; Magpantay LI; Candelaria PV; Penichet ML; Martínez-Maza O; Epeldegui M
Mol Cancer Ther; 2021 Sep; 20(9):1592-1602. PubMed ID: 34158342
[TBL] [Abstract][Full Text] [Related]
3. A rat monoclonal anti-(human CD2) and L-leucine methyl ester impacts on human/SCID mouse graft and B lymphoproliferative syndrome.
Bombil F; Kints JP; Havaux X; Scheiff JM; Bazin H; Latinne D
Cancer Immunol Immunother; 1995 Jun; 40(6):383-9. PubMed ID: 7627995
[TBL] [Abstract][Full Text] [Related]
4. The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice.
Gladue RP; Paradis T; Cole SH; Donovan C; Nelson R; Alpert R; Gardner J; Natoli E; Elliott E; Shepard R; Bedian V
Cancer Immunol Immunother; 2011 Jul; 60(7):1009-17. PubMed ID: 21479995
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo antitumor activity of a chimeric anti-CD19 antibody.
Pietersz GA; Wenjun L; Sutton VR; Burgess J; McKenzie IF; Zola H; Trapani JA
Cancer Immunol Immunother; 1995 Jul; 41(1):53-60. PubMed ID: 7543822
[TBL] [Abstract][Full Text] [Related]
6. Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates.
Kelley SK; Gelzleichter T; Xie D; Lee WP; Darbonne WC; Qureshi F; Kissler K; Oflazoglu E; Grewal IS
Br J Pharmacol; 2006 Aug; 148(8):1116-23. PubMed ID: 16847437
[TBL] [Abstract][Full Text] [Related]
7. Anti-CD20 monoclonal antibodies: historical and future perspectives.
Lim SH; Beers SA; French RR; Johnson PW; Glennie MJ; Cragg MS
Haematologica; 2010 Jan; 95(1):135-43. PubMed ID: 19773256
[TBL] [Abstract][Full Text] [Related]
8. Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody.
Hekman A; Honselaar A; Vuist WM; Sein JJ; Rodenhuis S; ten Bokkel Huinink WW; Somers R; Rümke P; Melief CJ
Cancer Immunol Immunother; 1991; 32(6):364-72. PubMed ID: 1706642
[TBL] [Abstract][Full Text] [Related]
9. Proteoglycan-targeted antibodies as markers on non-Hodgkin lymphoma xenografts.
Kopper L; Bankfalvi A; Mihalik R; Glant TT; Timar J
Cancer Immunol Immunother; 1990; 32(2):137-42. PubMed ID: 2289206
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibody uptake in B-cell lymphomas: experimental studies in nude mouse xenografts.
Schmid J; Möller P; Moldenhauer G; Dörken B; Bihl H; Matzku S
Cancer Immunol Immunother; 1993; 36(4):274-80. PubMed ID: 7679951
[TBL] [Abstract][Full Text] [Related]
11. A novel splice donor mutation in
Zhang X; Jiang W; Jin Z; Wang X; Song X; Huang S; Zhang M; Lu H
Front Oncol; 2023; 13():1282678. PubMed ID: 37901335
[TBL] [Abstract][Full Text] [Related]
12. In vitro immunization of Epstein-Barr virus-immortalized B cells augments antigen-specific antibody production.
Harada G; Matsumoto SE; Yamashita M; Fujii K; Shirahata S; Katakura Y
Cytotechnology; 2013 Dec; 65(6):979-83. PubMed ID: 23949581
[TBL] [Abstract][Full Text] [Related]
13. The Research Progress on Immortalization of Human B Cells.
Xu H; Xiang X; Ding W; Dong W; Hu Y
Microorganisms; 2023 Dec; 11(12):. PubMed ID: 38138080
[TBL] [Abstract][Full Text] [Related]
14. Development of new adherent mutant from human myeloma-derived cell line: in vitro model of anaplastic transformation of myeloma.
Jung KC; Park CS; Sohn HW; Kook MC; Chung DH; Choi YK; Hyun BH; Lee IS; Bae YM; Song HG; Park SH
Mol Cells; 1999 Dec; 9(6):657-61. PubMed ID: 10672934
[TBL] [Abstract][Full Text] [Related]
15. PDX Models in Theranostic Applications: Generation and Screening for B Cell Lymphoma of Human Origin.
Shmuel S; Monette S; Ibrahim D; Pereira PMR
Mol Imaging Biol; 2024 Apr; ():. PubMed ID: 38649626
[TBL] [Abstract][Full Text] [Related]
16. Latent EBV impairs immune cell signaling and enhances the efficacy of anti-CD3 mAb in Type 1 Diabetes.
Delgado AL; Preston-Hurlburt P; Lim N; Sumida TS; Long SA; McNamara J; Serti E; Higdon L; Herold KC
medRxiv; 2023 Jul; ():. PubMed ID: 37502867
[TBL] [Abstract][Full Text] [Related]
17. An aggressive mediastinal EBV-associated large B cell lymphoma.
Kurz KS; Noerenberg D; Schaich M; Bethge W; Horn H; Staiger AM; Fend F; Damm F; Ott G
Histopathology; 2024 Apr; ():. PubMed ID: 38566333
[No Abstract] [Full Text] [Related]
18. Use of Hu-PBL Mice to Study Pathogenesis of Human-Restricted Viruses.
Brunetti JE; Kitsera M; Muñoz-Fontela C; Rodríguez E
Viruses; 2023 Jan; 15(1):. PubMed ID: 36680271
[TBL] [Abstract][Full Text] [Related]
19. Lymphomas can develop from B cells chronically helped by idiotype-specific T cells.
Zangani MM; Frøyland M; Qiu GY; Meza-Zepeda LA; Kutok JL; Thompson KM; Munthe LA; Bogen B
J Exp Med; 2007 May; 204(5):1181-91. PubMed ID: 17485509
[TBL] [Abstract][Full Text] [Related]
20. Ex vivo stimulation of B cells latently infected with gammaherpesvirus 68 triggers reactivation from latency.
Moser JM; Upton JW; Gray KS; Speck SH
J Virol; 2005 Apr; 79(8):5227-31. PubMed ID: 15795307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
